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Abstract
Nasopharyngeal carcinoma (NPC) is a highly prevalent disease in Southeast Asia and its prevalence
is clearly affected by genetic background. Various theories have been suggested for its high
incidence in this geographical region but to these days no conclusive explanation has been
identified. Chromosomal imbalances identifiable through comparative genomic hybridization may
shed some light on common genetic alterations that may be of relevance to the onset and
progression of NPC. Review of the literature, however, reveals contradictory results among
reported findings possibly related to factors associated with patient selection, stage of disease,
differences in methodological details etc. To increase the power of the analysis and attempt to
identify commonalities among the reported findings, we performed a meta-analysis of results
described in NPC tissues based on chromosomal comparative genomic hybridization (CGH). This
meta-analysis revealed consistent patters in chromosomal abnormalities that appeared to cluster
in specific "hot spots" along the genome following a stage-dependent progression.
Background
Nasopharyngeal carcinoma (NPC) is a Epstein-Barr virus-
associated cancer [1] highly prevalent in Southeast Asia
and especially southern China where it occurs at a preva-
lence about a 100-fold higher compared with other popu-
lations not at risk [2,3]. Although environmental factors
may contribute to this geographical association [4], the
high prevalence of NPC in U.S. immigrants suggests a
genetic influence [5]. Indeed, genetic markers associated
with the disease have been proposed including an
enhanced or reduced prevalence of some HLA haplotypes
[6] or, more recently, a genomic region within chromo-
some 4 identified through genome-wide scanning of case
control studies of familiar NPC from the Guangdong
region [7].
Independently of the genetic root at the basis of its geo-
graphical prevalence, NPC is progressively characterized
by widespread genomic imbalances possibly occurring
before and during carcinogenesis [8]. Different strategies
of comparative genomic hybridization (CGH) have been
utilized to screen NPC for evidence of consistent chromo-
somal gains and losses along the progression of the dis-
ease [9-14]. However, most studies included a relatively
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small number of cases applied to different experimental
models including the analysis of cell lines, xenografts or
neoplastic tissues impairing the ability to interpreter the
significance and evaluate the true frequency of chromo-
some imbalances in NPC. In particular, stratification of
cases according to staging could not be performed at a
power that could yield statistically meaningful informa-
tion due to the limited sample population included in
individual studies. Therefore, we entertained a meta-anal-
ysis of available information based on CGH of NPC sam-
ples derived directly from neoplastic material and
excluding information derived from cell lines which
might skew the true in vivo prevalence although others
have shown a reasonable correlation between genetic
alterations observed in vivo and those identifiable through
the study of cell lines [15,16].
Six studies were identified that utilized directly tissue sam-
ples and contained sufficient information to allow a direct
cross comparison of the results among them [8-12,17]. In
this fashion, 188 NPC cases from Southern Asia were eval-
uated for which the CGH-derived information could be
related to clinical staging.
Results
Chromosomal imbalances in patients with NPC
The flow chart of the strategy applied for the meta-analysis
is summarized in Figure 1 (see also materials and meth-
ods). The complete meta-analysis of all available CGH
data revealed that chromosome gains were prevalent in
1q, 2q, 3q, 6q, 8q, 11q, 12p, 12q, 17p, and 17q (Figure 2).
Hot spots could be identified in several regions: the ones
with highest prevalence were in 1q, 3q, 8q, 12p, and 12q
displaying more than 20% frequency. Hot spots with
slightly lower prevalence (15 to 20%) could be identified
in, 2q, 6q, 11q, 17p, and 17q. Chromosome losses
occurred mainly on 3p, 8p, 11q, 13q, 14q, and16q.
Among them, losses in 3p, 11q, 14q, and 16q occurred
with more than 20% frequency while in 8p and 13q
occurred with 15%-20% frequency. In total 12 hot spots
were identified by this meta-analysis. Known oncogenes,
tumor suppressor genes or other NPC related genes
located in these hot-spots are presented in Table 1.
Two studies reported the EBV status of a tumor for a total
of 30 cases [10,17] In all cases, the tumors displayed evi-
dence of EBV presence. Because this information supports
with higher confidence the categorization of NPC to the
WHO EBV-related tumors, we performed a separate meta-
analysis only on these samples. The results were largely
similar to those observed in the whole population ana-
lyzed (Figure 3). However, additional regions were identi-
fied with high frequency of imbalances that could be best
explained by a higher sensitivity of the methodologies
applied in these particular studies. Alternatively, it is pos-
sible that the other studies included cases of tumors not
harboring EBV and, therefore, not canonically EBV-
related. In this particular though unlikely case, these 4 hot
spots could be considered DSA specifically linked to the
EBV etiopathogenesis.
Chromosomal imbalances according to WHO staging
When the information was available, cases of NPC were
grouped according to WHO staging [18]. One hundred-
eight cases could be collected of which 28 were grouped
as stage I-II and 80 as stage III-IV. Comparison of frequen-
cies in chromosomal imbalances was carried between the
two categories and their significance was examined based
on a Fisher's exact test. In general, the same patterns of
chromosomal gains or losses were seen in both categories
with a trend to higher frequencies in advanced stages (Fig-
ure 4). Statistical analysis identified specific areas whose
frequency of imbalances was significantly related to stage
(Table 2). Of interest were also areas of gain such as 3p,
8q, 12p, 12q or loss such as 14p and 14q where a similar
frequency was noted independently of stage suggesting
that, possibly, this represent earlier and more fundamen-
tal chromosomal aberrations that occur early during NPC
oncogenesis.
Putative sub-grouping of NPC cases according to 
relatedness of chromosomal imbalances
Clustering analysis was performed by combining gain and
loss data according to a binomial mathematical measure
in which lack of imbalances was assigned a value of 0 and
gain or losses were indiscriminately assigned a value of
one across the data set. Hot spots containing imbalances
Flow chart summarizing the strategy adopted for the meta- analysis of chromosomal imbalances associated with NPC Figure 1
Flow chart summarizing the strategy adopted for the meta-
analysis of chromosomal imbalances associated with NPC. 
The analysis was based on 6 studies whose information was 
comparable and reported on tissue samples eliminating stud-
ies reporting on cell lines or xenograft information [9-12, 17, 
51]. See Materials and Methods for details.Journal of Translational Medicine 2006, 4:4 http://www.translational-medicine.com/content/4/1/4
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occurring more that 20% of the times in the population
tested were then evaluated by selecting the single repre-
sentative region within each hot spot portraying the high-
est frequency value. This data set was, then, combined and
cluster analysis was performed (Figure 5). This explorative
test identified two sub groups of NPC predominantly
characterized by gains and the other by losses. In each cat-
egory two subgroups could be observed one in which
imbalances occurring in any stage of NPC were clustered
together (green boxes) and those predominantly occur-
ring in advanced stage NPC (blue boxes). Interestingly, a
sub group of NPC was identified that included chromo-
somal imbalanced detected only in NPC cases for which
there knowledge about EBV presence was suggesting that
either these studies were characterized by a different level
of resolution in identifying chromosomal imbalances or
that the NPC cases included in these studies represented a
biologically distinct subtype of cancer tightly linked to a
EBV-related etiology while the cases included in the other
studies represented a more heterogeneous population.
Discussion
Meta-analyses are a powerful tool that allows the identifi-
cation of patterns consistent in independent studies that,
therefore, permits segregating true biological entities from
artifactual findings related to biases associated with indi-
vidual studies. The present meta-analysis of NPC cases
explored the frequencies reported of chromosomal aber-
Frequency of chromosomal gains (panel A) or losses (panel B) in 188 samples derived from patients with NPC Figure 2
Frequency of chromosomal gains (panel A) or losses (panel B) in 188 samples derived from patients with NPC. The Y axis 
reports the frequency of chromosomal imbalances for individuals chromosome regions clustered into sections as described in 
the Materials and Methods. The X axis represents and ordered distribution of the chromosome analyzed. A cut-off of 0.15 cor-
responds to a frequency of imbalances higher than 15% arbitrarily selected to define "hot spots". A cut-off of .20 defines the 
predominant hot-spots used for clustering analysis.Journal of Translational Medicine 2006, 4:4 http://www.translational-medicine.com/content/4/1/4
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rations associated with NPC that could be detected with a
low resolution assay such as CGH. Consistently present
gains and losses could be identified which were defined as
"hot spots". Although some of them appeared to occur
with some reasonable frequency, none of them appeared
to be particularly predominant with the most frequent
chromosomal imbalances occurring at most in 30% of the
cases evaluated. This phenomenon implies that NPC
develops through the accumulation of multiple low-fre-
quency genetic events. The presence of several genes
known to be related to the etiopathogenesis of NPC in the
hot spots identified further supports the conclusion that
alterations in these genomic regions may play a promi-
nent role in the oncogenesis. In addition, the identifica-
tion of hot spots in which not know NPC-specific
biomarker as been reported (Table 1) proposes other
genomic regions of possible interest to be investigated for
the identification of unknown cancer inducing factors.
Stage specific and incremental imbalances were observed
with no hot spot identified in early cases (Stage I-II) that
could not be seen in later cases (Stage III-IV) but several
Table 1: Genes located in "hot spots" identified by the present meta-analysis
Ch Arm Host spot, DSAI Freq (%) Candidate NPC-related 
Genes
references
1 +1q + 1q22-q23.3 25.00 LAMC2 [13]
+ 1q31.1-q32.3 26.06
2 +2q + 2q31.1-q32.3 17.55
3 -3p - 3p12.3-p14.1 33.51 FHIT [31]
- 3p21.2-p21.33 30.32 RASSF1A,, Blu [32,33]
- 3p24.2-p26.3 29.26 RARβ2, RAF1 [13,34]
+3q + 3q26.2-q27.2 19.68 deltaN-p63 [35]
6 +6p +6p21.2-p23 23.33 E HSP70-2 [36]
8 +8q + 8q23.1-q24.11 22.87 MYC [37]
9 -9P - 9p21.1-p23 18.61 P14, p16, UBAPI, NGX6 [38–41]
11 +11q + 11q12.3-q13.5 16.49 Cyclin D1 [14]
-11q - 11q23.1-q25 29.79 TSLC1/IGSF4, [42]
12 +12p + 12p12.1-p12.2 36.17
+12p11.21-p11.22 34.04
+12q + 12q13.11-q14.1 35.11 MDM2, STAT2 [43,44]
13 -13q - 13q22.1-q31.3 18.61 EDNRB, LIG4 [45,46]
14 -14q - 14q21.1-q21.3 25.00
- 14q24.3 27.13 AKTI/PKB, SIVA [43]
15 +15q +15q21.3-q25.3 26.67 E DAPK2 (?) [47]
16 -16q - 16q13-q24.3 29.79 E-cadherin, BRD7 [48,49]
18 +18p +18p 20.00 S
+18q +18q21.1-q21.33 21.25 S
20 +20q +20q11.21-q13.13 30.00 E PLUNC (?) [50]
Frequency of chromosomal in 30 samples derived from patients with NPC known to contain EBV virus Figure 3
Frequency of chromosomal in 30 samples derived from patients with NPC known to contain EBV virus. The Y axis reports the 
frequency of chromosomal imbalances for individuals chromosome regions clustered into sections as described in the Materials 
and Methods. The X axis represents and ordered distribution of the chromosome analyzed.Journal of Translational Medicine 2006, 4:4 http://www.translational-medicine.com/content/4/1/4
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examples of incremental imbalances associated with
advanced NPC. Surprisingly, unique imbalances were
identified in cases in which the EBV status of the tumor
was reported. Although it is conceivable that those cases
in which EBV status was not reported may have represent
disease taxonomy un-related to the EBV etiopathogenesis
this possibility seems quite unlikely. First the cases ana-
lyzed were from an area of the World where EBV-associ-
ated NPC is endemic. Second, all cases in which the EBV
status was evaluated, its presence turned out to be evident
suggesting that also in the other cases the same results
could be expected. It is, therefore, possible, that the two
studies presenting this information [10,17]. were carried
out adopting methodologies characterized by different
Frequency of chromosomal gains (panel A) or losses (panel B) in 108 samples derived from patients with NPC of which 28  were grouped as WHO stage I-II (red line) and 80 as WHO stage III-IV (green line) Figure 4
Frequency of chromosomal gains (panel A) or losses (panel B) in 108 samples derived from patients with NPC of which 28 
were grouped as WHO stage I-II (red line) and 80 as WHO stage III-IV (green line). The Y axis reports the frequency of chro-
mosomal imbalances for individuals chromosome regions clustered into sections as described in the Materials and Methods. 
The X axis represents and ordered distribution of the chromosome analyzed.
Table 2: Significantly different frequencies of chromosomal 
imbalances in early compared to advanced NPC.
Selected Region Stage (%) Fisher's exact
I-II (n = 28) III-IV (n = 80)
Gain +1q22-q23.3 10.71 36.25 0.015
+1q31.1-q32.3 10.71 32.50 0.015
+18p 00.00 21.25 0.005
+18q21.1-q21.33 00.00 20.00 0.010
Loss -3p12.3-p14.1 14.29 42.50 0.010
-3p25.1-p26.3 10.71 37.50 0.008
-11q23.1-q25 10.71 33.75 0.026
-16q13-q24.3 14.29 37.50 0.032Journal of Translational Medicine 2006, 4:4 http://www.translational-medicine.com/content/4/1/4
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level of sensitivity in detecting chromosomal imbalances.
This question will need to be further addressed in future
studies.
Interestingly, NPC appeared to segregate, based on cluster
algorithms of relatedness, according to a general tendency
toward chromosomal loss or gain. It is only, within cate-
gory of loss or gain that imbalances present in early and
late stage NPC segregated from those occurring at a later
phase. This is reminiscent of the "tree model" of NPC
pathogenesis that we previously reported [4]. Whether,
this finding has a biological foundation or is related to a
different sensitivity of CGH in reporting gain or losses will
need also to be further explored.
Recently, Yan W et al [19] reported a novel study address-
ing chromosomal abnormalities associated with cervical
nodal metastases in NPC. Since this information was not
available at the time of our studies, we utilized this study
to validate the prediction power of our results on an inde-
pendent data set. In Yan's study, 23 samples of primary
NPC were compared with 9 samples derived from lymph
node metastases. A similar pattern of genomic imbalances
was seen in primary and metastatic tumors reflecting their
common clonal origin. Primary tumors were character-
ized by frequent gains of 5p, 12p, 12q and 18p and losses
of 1p, 3p, 9q that identified hot-spots (frequency = 15%)
as gains 12 12p and 12q and as losses in 1p, 3p, 9q, 14q
and 16 q (Figure 2). In addition, the areas of frequent
Correlation analysis based on clustering programs comparing the relatedness of the most frequently chromosomal imbalances  identified in this study (frequency at least > 20%) Figure 5
Correlation analysis based on clustering programs comparing the relatedness of the most frequently chromosomal imbalances 
identified in this study (frequency at least > 20%). Chromosomal regions representative of individual hot sports were selected 
as described in the material and methods. Distances are presented according to the φ 4 point correlation coefficient. Green 
boxes underline clusters including chromosomal aberrations found in early (Stage I-II) and late (Stage III-IV) NPC; blue boxes 
define clusters enriched with aberrations specific for late stage NPC and the red box defines chromosomal imbalances identi-
fied only by the studies in which the EBV status of the tumor was reported.Journal of Translational Medicine 2006, 4:4 http://www.translational-medicine.com/content/4/1/4
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aberrations that did not appear as hot spots in the meta-
analysis (< 15% frequency) were still characterized by
higher frequency than in the direction (gain or loss) indi-
cated by Yan's study. Thus, it appears that the results com-
piled by the meta-analysis could predict with high
accuracy the findings observed in an independent set of
individuals.
Chromosomal aberrations observed specifically in lymph
nodal metastases in Yan's study included also losses in 9p,
16p, 17q, 20q, 21p, 21q and 22q and gains in 8q and 8p
[19]. These findings diverged from the results of the meta-
analysis based on primary NPC samples with only loss of
9p and gain of 8q that were represented by hot spots. In
addition, loss of 16p was found in 100% on lymph nodal
metastases, the meta-analysis results demonstrated that
loss of 16p is more common in advanced stage primary
NPC with a frequency below 15% in early stages and
above 20% in stage III-IV. Thus, this region, may be a
potential area of interest when looking at genes that might
be associated with the metastatic potential of NPC and
other cancers [20-24]. However, also in this case, when
the results did not collimate the trends noted were in the
same direction. Overall, this meta-analysis aimed at uni-
fying other's results about chromosomal imbalances asso-
ciated with NPC development and progression, identified
consistent aberrations that could be identified in an inde-
pendent study. This suggests that these chromosomal
imbalances are strongly specific for the disease.
Materials and methods
Literature search
Searches were performed on PubMed and Medline using
the following combination of search terms: "NPC",
"Nasopharyngeal carcinoma", "and "CGH" and "compar-
ative genome hybridization". In total, 12 studies were
identified [8-13,17,25-29]., however, only 6 [8-12,17]
were eligible for further analysis based on the following
inclusion criteria: only NPC tumor biopsies were evalu-
ated (studies using NPC cell lines and xenograft cell lines
were excluded), the studies involved exclusively Southern
Asian NPC patients, applied comparable Chromosome
CGH analysis platforms, reported detailed CGH values
using similar thresholds for definition of chromosomal
loss or gain (if the normal DNA vs tumor DNA ratio was
< 0.75 the region was considered as a chromosomal gain;
if >1.20 it was considered a loss). A total of 188 NPC cases
were identified from the 6 studies including 3 studies
from Hong Kong, 2 from China, and 1 from Taiwan. Sig-
nificant chromosomal imbalances were detected in 155
patients. World Health Organization (WHO) staging [18]
was available in 108 cases; 28 belonged to early stage
(stage I and II), 80 belonged to advanced stage (stage III
and IV). EBV positive status was reported only in 30
patients from two studies.
Data integration
CGH data derived from the 6 studies was standardized by
dividing each chromosome arm into 20 sub-regions from
the centromere toward each telomere. Chromosome gains
and losses reported by the 6 studies were assigned to the
relevant chromosomal region and gains or losses were
recorded into two separate excel files reducing the infor-
mation into a binary model (1 = chromosome imbalance,
0 = no imbalance). Chromosomal loss or gain were
defined as previously stated according to a threshold sig-
nal intensity ratio between normal DNA over tumor DNA
< 0.75 (gain) or > 1.20 (loss). WHO staging of NPC and
EBV status were also entered in the data file.
Definition of hot spot and Disease Status-Associated 
Imbalance (DSAI)
Regions with high frequency of chromosomal imbalances
were considered 'hot spots". These were defined as chro-
mosome regions with frequency imbalance observed in at
least 15% of cases while the adjacent regions (boundaries
of the hot spot) displayed a drop if frequency of at least
2%. The 15% value was arbitrarily selected based on the
observation that the median frequency of chromosomal
gains was 5.8% (1st quartile = 2.7 and 3rd quartile = 11.2)
with an average of 7.7 ± 7.0 (Standard deviation, SD) and
of losses was 3.7% (1st quartile = 1.6 and 3rd quartile = 8)
with an average of 6.4 ± 7.4 (SD). A value of 15%
included, therefore, chromosomal regions with a fre-
quency of imbalances at least more than one SD above the
mean and above at least the 3rd quartile across the all data
set.
Disease status associated imbalance (DSAI) corresponded
to a chromosome region with a significantly high fre-
quency of imbalances in clinically relevant subgroups of
cases such as advanced versus early stage patients. The 1p,
16p, 19p, 19q, 22q regions and the whole Y chromosome
were not analyzed because they have been described to
yield false positives results in CGH analysis [8,11].
Finally, the X chromosome was also not analyzed due to
a rare prevalence of events associated with it and lack of
information about the patient's gender.
Statistical analysis
Chromosomal gains and losses were separately profiled
for all chromosomal regions previously defined arms by
assigning a binary value of 1 or 0 according to presence or
absence of imbalance for that region in each sample stud-
ied. Frequency of imbalances for each chromosomal
region analyzed was then calculated and graphically visu-
alized. Hot spots were selected for further analysis. Addi-
tionally, the frequency of chromosomal imbalances
observed in studies reporting the EBV-status of tumors
was also separately analyzed because of the higher confi-
dence that these tumors represented classical EBV-Journal of Translational Medicine 2006, 4:4 http://www.translational-medicine.com/content/4/1/4
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induced NPC. A two-tailed Fisher's exact test was applied
to explore the strength of relationships between given
chromosomal imbalances and stages of NPC in order to
identify DSAI. Based on hot spots and DSAI, a hierarchical
clustering analysis [30] was performed to explore possible
correlations among distinct chromosomal regions where
imbalances were frequent. A flow chart representing the
procedure of the meta-analysis is shown in Figure 1.
Clustering algorithms
Hot spots with a frequency above 205 were selected for
clustering analysis to identify potential subgroups of NPC
with a defined pattern of genetic imbalances. Within in
each spot a representative region was selected by choosing
the region associated with the highest frequency on
imbalances. Data from each of the selected region was
gathered in a separate data base assigning a value of 0 to
individual cases where no genetic imbalances were
observed and of 1 to either losses or gains. In this fashion
chromosomal imbalances could be clustered independ-
ently of their genetic tendency toward loss or gain. Hierar-
chical clustering was then carried on SPSS 10.0 based on
hot-spot ranking values giving an approximation of rela-
tionship among various imbalances measured according
to the Φ 4 point correlation coefficient.
This article was partly supported by a grant (30371535/
C030310) from National Natural Science Foundation of
China.
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